DIAMEDICA THERAPEUTICS INC
NASDAQ
US Flag
DMAC

DMAC
DIAMEDICA THERAPEUTICS INC
US Flag
NASDAQ
 
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E

DMAC Stock Chart

Financials

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: ---
DiaMedica Therapeutics Inc is a Canada-based clinical-stage biopharmaceutical company, which focuses on recombinant proteins and monoclonal antibodies. The Company focuses on the discovery and development of treatments for stroke and other vascular diseases. It operates through segment, which is discovery and development of recombinant proteins and monoclonal antibody technology applications to treat large unmet diseases, including acute vascular disease of the brain, kidneys and heart. Its product, DM199, is a recombinant human tissue kallikrein-1 protein engineered to duplicate the actions of the naturally occurring human kallikrein-1 protein produced in the pancreas, kidneys and salivary glands of humans as a response to oxidative stress challenges. Its drug, Recombinant tissue plasminogen activator, is intended for the treatment of acute ischemic stroke (AIS). DM199 has also completed a Phase I/II clinical trials in Type 2 diabetic patients.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out